<%@ Page Title="" Language="C#" MasterPageFile="~/masterpages/module.master" AutoEventWireup="true" CodeFile="references.aspx.cs" Inherits="secure_modules_module3_references" %>

<asp:Content ID="Content1" ContentPlaceHolderID="contentBreadcrumb" Runat="Server">
    Diagnozowanie i ocena \ Piśmiennictwo
</asp:Content>
<asp:Content ID="Content2" ContentPlaceHolderID="contentSideBar" Runat="Server">
</asp:Content>
<asp:Content ID="Content3" ContentPlaceHolderID="contentMain" Runat="Server">
    <div class="module3page">
        <h1>
            Piśmiennictwo</h1>
            <div class="icon_reading">
        <ul class="references">
           <li><span>Edwards RG, Barlow JH, Turner AP. Experiences of diagnosis and treatment among people with multiple sclerosis. <i>J Eval Clin Pract</i> 2008; 14(3): 460−4.</span></li>
            <li><span>Poser CM, Paty DW, Scheinberg L,<i> et al</i>. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. <i>Ann Neurol</i> 1983; 13(3): 227−31.</span></li>
            <li><span>McDonald WI, Compston A, Edan G, <i>et al</i>. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. <i>Ann Neurol</i> 2001; 50(1): 121–7.</span></li>
            <li><span>Polman CH, Reingold SC, Edan G, <i>et al</i>. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. <i>Ann Neurol</i> 2005; 58(6): 840−6.</span></li>
             <li><span>Polman CH, Reingold SC, Banwell B, <i>et al</i>. Diagnostic criteria for multiple sclerosis: 2010 revisions to the “McDonald Criteria”. <i>Ann Neurol</i> 2011; 69(2): 292−302.</span></li>
            <li><span>Martin J, Lowenstein DH, Hauser SL in Harrison’s Neurology in Clinical Medicine. Ed Hauser SL. Hill Companies, Inc. 2006; p17−23.</span></li>
            <li><span>Schumacher G, Beebe G, Kibler R, et al. Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. <i>Ann N Y Acad Sci</i> 1965; 122: 552–68.</span></li>
            <li><span>Wingerchuk DM, Lennon VA, Pittock SJ, <i>et al</i>. Revised diagnostic criteria for neuromyelitis optica.<i> Neurology</i>  2006; 66(10): 1485−9.</span></li>
             <li><span>Miller D, Weinshenker B, Fillipi M, <i>et al</i>. Differential diagnosis of suspected multiple sclerosis: a consensus approach <i>Mult Scler</i> 2008; 14(9): 1157–74.</span></li>
            <li><span>Marrie RA, Horwitz R, Cutter G, <i>et al</i>. Comorbidity delays diagnosis and increases disability at diagnosis in MS. <i>Neurology</i> 2009; 72(2): 117−24.</span></li>
            <li><span> Fisniku LK, Brex PA, Altmann DR, <i>et al</i>. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.<i> Brain</i>  2008; 131(Pt 3): 808−17.</span></li>
            <li><span>Okuda DT, Mowry EM, Beheshtian A, <i>et al</i>. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. <i>Neurology</i> 2009; 72(9): 800–5.</span></li>
             <li><span>Lebrun C, Bensa C, Debouverie M, <i>et al</i>. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow up of 70 patients. <i>Arch Neurol</i> 2009; 66(7): 841–6.</span></li>
            <li><span>Siva S, Saip S, Altintas A, <i>et al</i>. Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory demyelinating disease. <i>Mult Scler</i> 2009; 15(8): 918–27.</span></li>
            <li><span>Okuda DT, Mowry EM, Cree BA, <i>et al</i>. Asymptomatic spinalcord lesions predict disease progression in radiologically isolated syndrome.<i> Neurology</i>  2011; 76(8): 686–92.</span></li>
            <li><span>Barkhof F, Filippi M, Miller DH,<i> et al</i>. Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite multiple sclerosis. <i>Brain</i> 1997; 120(Pt 11): 2059–69.</span></li>
            <li><span>Tintore M, Rovira A, Martinez MJ, <i>et al</i>. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR<i> Am J Neuroradiol</i> 2000; 21(4): 702–6.</span></li>
            <li><span>McHugh JC, Galvin PL, Murphy RP. Retrospective comparison of the original and revised McDonald Criteria in a general neurology practice in Ireland. <i>Mult Scler</i> 2008; 14(1): 81–5.</span></li>
            <li><span>Albertyn C, O’Dowd S, McHugh J, <i>et al</i>. Compliance with McDonald criteria and red flag recognition in a general neurology practice in Ireland. <i>Mult Scler</i> 2010; 16(6): 678–84.</span></li>
            <li><span>Swanton JK, Fernando K, Dalton CM, <i>et al</i>. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. <i>J Neurol Neurosurg</i> Psychiatry 2006; 77(7): 830–3.</span></li>
             <li><span>Swanton JK, Rovira A, Tintore M, <i>et al</i>. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. <i>Lancet Neurol</i> 2007; 6(8): 677–86.</span></li>
            <li><span>Montalban X, Tintore M, Swanton J, <i>et al</i>. MRI criteria for MS in patients with clinically isolated syndromes. <i>Neurology</i> 2010; 74(5): 427–34.</span></li>
            <li><span>Tur C, Tintore M, Rovira A, <i>et al</i>. Very early scans for demonstrating dissemination in time in multiple sclerosis. <i>Mult Scler</i> 2008; 14(5): 631–5.</span></li>
            <li><span>Rovira A, Swanton J, Tintore M, <i>et al</i>. A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. <i>Arch Neurol</i> 2009; 66(5): 587−92.</span></li>
             <li><span>Boesch C. Molecular aspects of magnetic resonance imaging and spectroscopy. Mol <i>Aspects Med</i> 1999; 20(4−5): 185−318.</span></li>
            <li><span>Wattjes MP, Harzheim M, Lutterbey GG, <i>et al</i>. Does high field MRI allow an earlier diagnosis of multiple sclerosis? <i>J Neurol</i> 2008; 255(8): 1159−63.</span></li>
            <li><span>Fauci AS, Braunwald E, Kasper DL <i>et al</i>. Multiple sclerosis and other demyelinating diseases. Chapter 375 in:<i> Harrison’s Principles of Internal Medicine</i>. 17th ed. New York, NY: McGraw-Hill; 2008.</span></li>
            <li><span> Zivadinov R, Leist TP. Clinical-magnetic resonance imaging correlations in multiple sclerosis. <i>J Neuroimaging</i> 2005; 15(4 Suppl): 10S−21S.</span></li>
             <li><span>Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. <i>Curr Opin Neurol</i> 2002; 15(3): 239−45.</span></li>
            <li><span>Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. <i>J Neuroimmunol</i> 2006; 180(1): 17–28.</span></li>
            <li><span>Compston A, Confavreux C, Lassmann H <i>et al</i>. McAlpine’s Multiple Sclerosis. 4th ed. London: Churchill Livingstone; 2006.</span></li>
            <li><span>Mehling M, Kuhle J, Regeniter A. 10 most commonly asked questions about cerebrospinal fluid characteristics in demyelinating disorders of the central nervous system. <i>Neurologist</i> 2008; 14(1): 60–5.</span></li>
            <li><span>Bourahoui A, de Seze J, Guttierez R, <i>et al</i>. CSF isoelectrofocusing in a large cohort of MS and other neurological diseases. <i>Eur J Neurol</i> 2004; 11(8): 525–9.</span></li>
            <li><span>Zaffaroni M. Cerebrospinal fluid findings in Devic’s neuromyelitis optica. <i>Neurol Sci</i> 2004; 25(Suppl 4): S368–70. </span></li>
            <li><span>Tintore M, Rovira A, Rio J, <i>et al</i>. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? <i>Neurology</i> 2008; 70(13 Pt 2): 1079−83.</span></li>
            <li><span>Hassan-Smith G and Douglas MR. Epidemiology and diagnosis of multiple sclerosis. <i>Br J Hosp Med</i> (Lond) 2011; 72(10): M146−53.</span></li>
             <li><span>Chiappa K. Pattern-shift visual, brainstem auditory and short-latency somatosensory evoked potentials in multiple sclerosis. <i>Ann N Y Acad Sci</i> 1984; 436: 315–27.</span></li>
            <li><span>Gronseth GS, Ashman EJ. Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review).<i>Neurology</i>  2000; 54(9): 1720–5.</span></li>
            <li><span>Pelayo R, Montalban X, Minoves T, <i>et al</i>. Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?<i> Mult Scler</i> 2010; 16(1): 55−61.</span></li>
            <li><span>Giesser BS. Diagnosis of multiple sclerosis. <i>Neurol Clin</i> 2011; 29(2): 381−8.</span></li>
             <li><span>Graber JJ and Dhib-Jalbut S. Biomarkers of disease activity in multiple sclerosis. <i>J Neurol Sci</i> 2011; 305(1−2): 1−10.</span></li>
            <li><span>Multiple Sclerosis Society; Frohman E M, in A Practical Primer: Multiple Sclerosis for the Physician Assistant Ed; Frohman T, O’Donoghue D, and Northrop D. 2011: 71−81.</span></li>
            <li><span>Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). <i>Neurology</i> 1983; 33(11): 1444−52.</span></li>
            <li><span>Kurtzke JF. Historical and clinical perspectives of the expanded disability status scale. <i>Neuroepidemiology</i> 2008; 31(1): 1−9.</span></li>
             <li><span> Rudick RA, Polman CH, Cohen JA, <i>et al</i>. Assessing disability progression with the Multiple Sclerosis Functional Composite. <i>Mult Scler</i> 2009; 15(8): 984−97.</span></li>
            <li><span>Rudick R, Antel J, Confavreux C, <i>et al</i>. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force.<i> Ann Neurol</i>  1997; 42(3): 379−82.</span></li>
            <li><span>Fischer JS, Jack AJ, Knicker JE, Rudick RA, Cutter G. <i>Administration and scoring manual for the Multiple Sclerosis Functional Composite Measure (MSFC)</i>. Canada: Demos, 1999.</span></li>
            <li><span>Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests.<i> Arch Phys Med Rehabil</i>  1988; 69(10): 850−4.</span></li>
            <li><span>Gronwall DM. Paced auditory serial-addition task: a measure of recovery from concussion. <i>Percept Mot Skills</i> 1977; 44(2): 367−73.</span></li>
            <li><span>Cutter GR, Baier ML, Rudick RA, <i>et al</i>. Development of a multiple sclerosis functional composite as a clinical trial outcome measure.<i> Brain</i> 1999; 122(Pt 5): 871−82.</span></li>
            <li><span>Kalkers NF, Bergers L, de Groot V, <i>et al</i>. Concurrent validity of the MS Functional Composite using MRI as a biological disease marker. <i>Neurology</i> 2001; 56(2): 215−19.</span></li>
            <li><span> Kalkers NF, Bergers E, Castelijns JA, <i>et al</i>. Optimizing the association between disability and biological markers in MS. <i>Neurology</i> 2001; 57(7): 1253−8.</span></li>
             <li><span>Fisher E, Rudick RA, Cutter G, <i>et al</i>. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients.<i> Mult Scler</i>  2000; 6(6): 373−7.</span></li>
            <li><span>Roxburgh RH, Seaman SR, Masterman T,<i> et al</i>. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. <i>Neurology</i> 2005; 64(7); 1144−51.</span></li>
        </ul>
        </div>
    </div>
</asp:Content>

